Nina Kjellson

PrimeraDx, Inc. develops and commercializes molecular diagnostics systems. It offers ICEPlex System, an open platform that allows clinical researchers to design their assays for the development of multiplexed, multimodal, and quantitative in vitro diagnostic to simultaneously interrogate dozens of biomarkers in the same reaction. The company's ICEPlex System also enables to design complex multi-modal assays that test for disparate target types, such as SNPs, expression biomarkers, miRNAs, and fusion genes, as well as addresses research challenges in oncology, infectious diseases, translational medicine research, and pharma quality control. It also focuses on developing oncology products that are intended to support cancer research, diagnostics, and therapeutics; and companion diagnostics solutions that help pharmaceutical companies to design, develop, and validate custom CDx tests. The company was founded by Vladimir I. Slepnev in 2004 and is headquartered in Mansfield, MA.

Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA.

Lycera Corp. develops novel oral medicines for treating autoimmune diseases and cancer. It specializes in immune metabolism, cell signaling and immune cell differentiation. The firm designed gut-directed ATPase modulator, designated LYC-30937, for the treatment of inflammatory bowel disease, and oral RORgamma agonists for diverse applications in immune-oncology. The company was founded in 2006 by Anthony William Opipari, Jr., and Gary D. Glick and is headquartered in Ann Arbor, MI.

CNS Therapeutics, Inc. develops and manufactures drug delivery products. The company was founded in 2007 and is headquartered in St. Paul, MN.

Cebix, Inc. provided treatments for complications of diabetes. It developed Ersatta, a proprietary disease-modifying replacement peptide for the treatment of complications associated with diabetes, including diabetic peripheral neuropathy, autonomic neuropathy, nephropathy, and retinopathy. The company was founded by John Wahren and Lars G. Ekman in 2008 and was headquartered in San Diego, CA.

Panacea Acquisition Corp. II operates as a blank check company. It seeks to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 14, 2021 and is headquartered in San Francisco, CA.

Predilytics, Inc. provides advanced healthcare analytic solutions. The firm engages in the provision of advanced healthcare analytic solutions to health plans, providers, and other risk-bearing entities. It applies its patented analytic tools to transform structured and unstructured client data, along with external data sources, into actionable insights. The company was founded by Hariharan Sundram and Chris Johnson in 2011 and is headquartered in Burlington, MA.

Labrys Biologics, Inc. provides biotechnology services. It is a venture-financed development stage biotechnology company, which focuses on treatments for chronic migraine. The company was founded by Corey S. Goodman in 2012 and is headquartered in San Francisco, CA.

The Henry J. Kaiser Family Foundation, do-business-as Kaiser Family Foundation (KFF), is a non-profit, private operating foundation headquartered in San Francisco, California. The firm was founded in 1948, but it was completely remade in 1991. The foundation focuses on national health issues and the US role in global health policy. KFF develops and runs their own policy analysis, journalism and communications programs, sometimes in partnership with major news organizations.

Nereus Pharmaceuticals, Inc. is a drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. Nereus' discovery portfolio also includes additional drug candidates for oncology, inflammation, and infectious diseases. The company was founded in 1998 and is headquartered in San Diego, CA.

Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO.

InterWest Partners LLC (InterWest Partners) is a venture capital firm founded in 1979 by Wally Hawley, Scott Hedrick and Gene Barth. The firm is headquartered in San Francisco, California.

Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States.

Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA.

Ocera Therapeutics, Inc. is a San Diego based, privately held biopharmaceutical company founded in January 2005 by Dr. Eckard Weber and Dr. Laurent Fischer. Ocera focuses on the development of novel therapeutics in the areas of liver and gastrointestinal diseases.

PACT Pharma, Inc. develops pharmaceutical products. It offers personalizes adoptive cell therapies with neoantigen-targeted T cells against cancer. The company is headquartered in South San Francisco, CA.

Intrepida Bio, Inc. discovers and develops medicines to modulate the innate immune system to fight cancer and other diseases. The company was founded by Joel F. Martin and Olivier Laurent and is headquartered in San Diego, CA.

Essential Access Health provides family healthcare services. Its services include clinic support initiatives, advanced clinical research, provider training, patient education, advocacy, and consumer awareness. The company was founded in 1968 and is headquartered in Los Angeles, CA.

Alt12 Apps, Inc. provided mobile application platform. It published fertility, pregnancy, and general health tracking mobile applications. The firm’s products included BabyBump, a pregnancy application that keeps soon-to-be parents informed about their pregnancy progress and enables tracking and sharing the experience with family, friends and a community of moms around the world; Pink Pad, a health and lifestyle tracker with integrated community to connect women around the world; and Kidfolio, a digital scrapbook and social network for parents. The company was founded by Jennifer Wong and Casey Sackett in 2009 and was headquartered in San Francisco, CA.

Dauntless Pharmaceuticals, Inc. develops specialty therapeutics via a one-asset, one-company model that is structured to facilitate operational efficiencies. The company was founded by Joel F. Martin and Michael F. Powell in May 2015 and is headquartered in San Diego, CA.

Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA.

Vineti, Inc. develops software for scaling and digital solutions for cell and gene therapies. The firm focuses on enabling life changing autologous therapies, supporting standards, and developing infrastructure that will expand patient access through expedited discovery, delivery and regulation in the field. The company was founded by Heidi Hagen, Malek Faham, Amy DuRoss and Razmik Abnous and is headquartered in San Francisco CA.

Annum Health, Inc. engages in the provision of health services. It is working with medical providers and employers, and developed a stigma-free regimen. The company was founded by Michael B. Laskoff, Mark Willenbring and Lauren Wolfe in 2016 and is headquartered in New York, NY.

Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.

Sequel Pharmaceuticals, Inc. engaged in the development of cardiovascular drug. The company was founded in 2007 and was headquartered in San Diego, CA.

Canaan Management, Inc. (Canaan Management) is a venture capital firm founded in 1987 by Eric A. Young. The firm is headquartered in Westport, CT.

Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021.

Part of Canaan Management, Inc., Canaan Partners XI LLC provides investment services. The private company is based in Wilmington, DE.

Rondo Therapeutics, Inc. develops bispecific therapeutic antibodies to fight cancer. The American company was founded by Nathan D. Trinklein, Shelley Force Aldred. Shelley Force Aldred has been the CEO since incorporation.

Girl Effect is an international non-profit organization that builds media for girls. The non-profit company is based in London, UK. The British company helps girls navigate their options and prioritize through their local brands and network of offices, reaching girls online and offline via girl-centered media and technology. It was founded in 2004, and the CEO is Farah Ramzan Golant.

CinRx Pharma LLC develops biopharmaceutical products. It provides therapeutics in a novel way that meets the modern paradigm of drug development. The company was founded by Jonathan L. Isaacsohn in 2015 and is headquartered in Cincinnati, OH.

Proxygen Co. is an American biotech company focused on the discovery and development of molecular glue degraders against targets of unmet medical need across various indications. Proxygen's headquarters and laboratory operations are based in an undisclosed location, and the private company employs talent both locally and remotely all over. The company maintains strategic partnerships with Merck & Co, Boehringer Ingelheim, and Merck KGaA to co-create synergies along the drug development pipeline.